Development of Clostridium bolteae vaccine continues to advance

A new vaccine under development to fight against Clostridium bolteae, a bacteria responsible for gastrointestinal issues prevalent in 90 percent of autistic children, is steadily advancing towards a market release.

The vaccine was developed in April by Researchers at the University of Guelph to kill the C. bolteae bacteria and is considered to be a huge breakthrough for those that suffer from the symptoms associated with an infection, most of whom are autistic children. Symptoms include chronic gastrointestinal issues such as diarrhea and constipation.

The vaccine works by attacking the carbohydrates on the surface of the C. bolteae bacteria and increasing antibodies. In a pre-clinical trial with rabbits, the vaccine was proven to be effective.

"This is the first vaccine designed to control constipation and diarrhea potentially caused by C. bolteae and perhaps control autism-related symptoms associated with this microbe," Guelph University Professor Mario Monteiro said.

The vaccine and its advancements have been published in the Vaccine journal. Although it was proven successful, more work must be done before it is market-ready, Monteiro said. The vaccine must still be refined and tested in human trials, a process which may take up to 10 years.